Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$59.56−1.79 (-2.92%)
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
Bristol Myers Squibb cash
Cash and short-term investments held at the end of each period.
Bristol Myers Squibb's cash was $12.58B at Sep 30, 2026. For fiscal 2025 it was $10.67B, down 1.7% from the year before. Over ten years it grew 9.6% a year on average. The highest annual figure on record is $17.30B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.67B | -1.7% |
| FY2024 | Dec 31, 2024 | $10.86B | -12.0% |
| FY2023 | Dec 31, 2023 | $12.34B | +30.5% |
| FY2022 | Dec 31, 2022 | $9.46B | -45.4% |
| FY2021 | Dec 31, 2021 | $17.30B | +6.4% |
| FY2020 | Dec 31, 2020 | $16.26B | +2.5% |
| FY2019 | Dec 31, 2019 | $15.87B | +81.2% |
| FY2018 | Dec 31, 2018 | $8.76B | +28.6% |
| FY2017 | Dec 31, 2017 | $6.81B | +7.3% |
| FY2016 | Dec 31, 2016 | $6.35B | +48.7% |
| FY2015 | Dec 31, 2015 | $4.27B | -42.6% |
| FY2014 | Dec 31, 2014 | $7.44B | +64.3% |
| FY2013 | Dec 31, 2013 | $4.53B | +60.0% |
| FY2012 | Dec 31, 2012 | $2.83B | -67.6% |
| FY2011 | Dec 31, 2011 | $8.73B | +19.6% |
| FY2010 | Dec 31, 2010 | $7.30B | -14.2% |
| FY2009 | Dec 31, 2009 | $8.51B | +3.0% |
| FY2008 | Dec 31, 2008 | $8.27B | +358.9% |
| FY2007 | Dec 31, 2007 | $1.80B | -10.8% |
| FY2006 | Dec 31, 2006 | $2.02B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.58B | -23.8% |
| Q2 FY2026 | Jun 30, 2026 | $11.07B | -18.7% |
| Q1 FY2026 | Mar 31, 2026 | $10.49B | -11.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.67B | -1.7% |
| Q3 FY2025 | Sep 30, 2025 | $16.50B | +103.8% |
| Q2 FY2025 | Jun 30, 2025 | $13.62B | +104.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.78B | +21.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.86B | -12.0% |
| Q3 FY2024 | Sep 30, 2024 | $8.10B | +4.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.66B | -24.2% |
| Q1 FY2024 | Mar 31, 2024 | $9.67B | +3.8% |
| Q4 FY2023 | Dec 31, 2023 | $12.34B | +30.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.74B | -16.3% |
| Q2 FY2023 | Jun 30, 2023 | $8.78B | -34.6% |
| Q1 FY2023 | Mar 31, 2023 | $9.32B | -38.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.46B | -45.4% |
| Q3 FY2022 | Sep 30, 2022 | $9.25B | -42.2% |
| Q2 FY2022 | Jun 30, 2022 | $13.44B | +0.7% |
| Q1 FY2022 | Mar 31, 2022 | $15.18B | +14.4% |
| Q4 FY2021 | Dec 31, 2021 | $17.30B | +6.4% |
| Q3 FY2021 | Sep 30, 2021 | $16.00B | -25.8% |
| Q2 FY2021 | Jun 30, 2021 | $13.34B | -39.6% |
| Q1 FY2021 | Mar 31, 2021 | $13.27B | -29.2% |
| Q4 FY2020 | Dec 31, 2020 | $16.26B | +2.5% |
| Q3 FY2020 | Sep 30, 2020 | $21.58B | -33.7% |
| Q2 FY2020 | Jun 30, 2020 | $22.09B | -24.8% |
| Q1 FY2020 | Mar 31, 2020 | $18.75B | +114.0% |
| Q4 FY2019 | Dec 31, 2019 | $15.87B | +81.2% |
| Q3 FY2019 | Sep 30, 2019 | $32.54B | +376.5% |
| Q2 FY2019 | Jun 30, 2019 | $29.36B | +383.2% |
| Q1 FY2019 | Mar 31, 2019 | $8.76B | +29.5% |
| Q4 FY2018 | Dec 31, 2018 | $8.76B | +28.6% |
| Q3 FY2018 | Sep 30, 2018 | $6.83B | -4.1% |
| Q2 FY2018 | Jun 30, 2018 | $6.08B | -6.6% |
| Q1 FY2018 | Mar 31, 2018 | $6.77B | +10.8% |
| Q4 FY2017 | Dec 31, 2017 | $6.81B | +7.3% |
| Q3 FY2017 | Sep 30, 2017 | $7.12B | – |
| Q2 FY2017 | Jun 30, 2017 | $6.51B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.11B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.35B | – |
See a number that looks wrong?